In a nutshell This study investigated the effects of brentuximab vedotin in patients with relapsed/refractory Hodgkin lymphoma after stem cell transplant. Brentuximab vedotin appeared to be effective and safe for these patients. Some background Many patients with Hodgkin lymphoma (HL) are cured by standard therapies. However, some patients lose...
Read MoreTreatment(s) now being considered-Bone marrow transplant Posts on Medivizor
Pre-stem cell transplant BEAM versus FEAM for Hodgkin’s lymphoma
In a nutshell This study compared the safety and effectiveness of BEAM (carmustine, etoposide, cytarabine, melphalan) and FEAM (fotemustine instead of carmustine) chemotherapy regimens in patients with Hodgkin's lymphoma. This study concluded that these regimens are similarly effective, but FEAM was associated with more severe side effects. Some...
Read MoreIs tandem stem cell transplantation effective in high risk relapsed/refractory Hodgkin lymphoma
In a nutshell This study investigated the effect of tandem stem cell transplantation (SCT) in patients with high-risk relapsed/refractory Hodgkin Lymphoma (HL). The main finding was that patients treated with tandem SCT had greater progression-free survival than those without. Some background A SCT involves the transfer of stem cells into the patient to...
Read MoreWhat are the long-term outcomes for HL patients receiving plerixafor before a stem cell transplant?
In a nutshell This study compared the long-term outcomes of Hodgkin’s lymphoma (HL) patients who received plerixafor (Mozobil) to those who did not prior to autologous stem cell transplantation (autoSCT). This study concluded that plerixafor-treated patients had similar outcomes as patients who received conventional regimens. Some background...
Read MoreDoes high-dose GBM chemotherapy lead to better post-stem cell transplant outcomes compared to BEAM in refractory or relapsed Hodgkin’s lymphoma patients?
In a nutshell This study investigated the outcomes of primary refractory or relapsed Hodgkin’s lymphoma (HL) patients who received GBM (gemcitabine, busulfan, melphalan) or BEAM (carmustine, etoposide, cytarabine, melphalan) chemotherapy before autoSCT (autologous stem cell transplantation). This study concluded that GBM improved patient outcomes...
Read MoreWhat are the long-term outcomes after plerixafor and G-CSF before stem cell transplantation?
In a nutshell This study investigated the long-term outcomes of patients with non-Hodgkin’s lymphoma (NHL) or multiple myeloma (MM) who received plerixafor (Mozobil) or placebo combined with G-CSF (granulocyte colony stimulating factor) before a stem cell transplant (SCT). This study concluded that adding plerixafor to G-CSF did not negatively...
Read MoreDo two cycles of stem cell therapy lead to longer progression free survival in relapsed or refractory HL patients?
In a nutshell This study determined if progression-free survival (time from treatment before disease progression) could be improved in patients with relapsed or refractory Hodgkin’s lymphoma (HL) who received two cycles (tandem) of autologous hematopoietic stem cell transplantation (AHSCT). This study concluded that tandem AHSCT appears effective...
Read MoreHaploidentical stem cell transplant after failed autologous stem cell transplant: Lower risk of disease progression compared to identical-matched donors
In a nutshell This study examined the effect of donor type on allogeneic stem cell transplant outcomes in patients with relapsed Hodgkin lymphoma. This study reported reduced disease progression in patients with partially matched donors compared to identical matches. Some background While Hodgkin lymphoma is a curable disease, some patients...
Read MoreUse of brentuximab vedotin, nivolumab, and pembrolizumab for treating patients with relapsed or refractory Hodgkin lymphoma
In a nutshell This study looked at the use of brentuximab vedotin (Adcetris), nivolumab (Opdivo), and pembrolizumab (Keytruda) in treating patients with relapsed or refractory Hodgkin lymphoma. The study concluded that all three medications are very effective at treating patients with relapsed or refractory Hodgkin lymphoma. Some...
Read MoreThe use of donor stem cell transplantation in patients with relapsed Hodgkin lymphoma
In a nutshell The authors examined haploidentical (matched donor) stem cell transplantation (haplo-SCT) as a treatment for patients who relapsed after autologous stem cell transplantation. The study concluded that haplo-SCT is a valid treatment for patients with relapsed Hodgkin lymphoma. Some background Most cases of Hodgkin lymphoma (HL) can be...
Read MoreUse of brentuximab vedotin in Hodgin lymphoma patients before allogenic stem cell transplantation
In a nutshell This study examined the outcomes for patients who received brentuximab vedotin before allogenic stem cell transplantation. The authors concluded that patients treated with brentuximab vedotin had generally good outcomes. Some background Hodgkin lymphoma (HL) is generally considered a curable disease. However, some patients will not...
Read MoreComparing patient outcomes for different sources of stem cells
In a nutshell This study compared three sources of stem cells for patients receiving allogenic stem cell transplantation. The authors suggested that stem cells from familial haploidentical donors can lead to better patient outcomes. Some background Hodgkin lymphoma (HL) is generally considered curable. However, some cases do not respond to...
Read More
